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Osteoporosis is a systemic bonemetabolic disease that is highly prevalent in the elderly population, particularly in postmenopausal
women, which results in enhanced bone fragility and an increased susceptibility to fractures. However, the underlying molecular
pathogenesismechanisms still remain to be further elucidated. In this study, in a rat ovariectomy- (OVX-) induced postmenopausal
osteoporosis model, aberrant expression of amicroRNAmiR-142-5p and vascular cell adhesionmolecule 1 (VCAM-1) was found by
RNA sequencing analysis and qRT-PCR. Using a dual-luciferase reporter assay, we found that miR-142-5p can bind to and decrease
expression of VCAM-1 mRNA. Such reduction was prohibited when the miR-142-5p binding site in VCAM-1 3󸀠UTR was deleted,
andWestern blotting analyses validated the fact thatmiR-142-5p inhibited the expression ofVCAM-1 protein. Bonemarrow-derived
mesenchymal stem cells (BMMSCs) transfected with miR-142-5p showed a significantly decreased migration ability in a Transwell
migration assay. Collectively, these data indicated the important role ofmiR-142-5p in osteoporosis development involving targeting
VCAM-1 and inhibiting BMMSC migration.
1. Introduction
Postmenopausal osteoporosis (OPM) is the most common
type of osteoporosis. As a result of the decrease in post-
menopausal estrogen levels, bone microstructure deterio-
rates, bone mineral density (BMD) decreases, and bone
fragility increases, with bone fractures often occurring in
the severe cases [1, 2]. At present, the incidence of OPM in
women over 50 years of age is higher than 50%, and the
world incidence of OPM fractures has increased by 18% in
five years, which seriously affects the health and quality of
life of middle-aged and old women [3]. While bone marrow-
derived mesenchymal stem cells (BMMSCs) can differentiate
into osteoblasts and are known to play an important role
in bone development, regeneration, and repair, as a leading
causative event of the process leading to osteoporosis, the
osteogenic differentiation of BMMSCs has been shown to
be reduced [4, 5]. At present, the clinical treatments of
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Figure 1: Representative images of H&E-stained sections of femurs (at the lower secondary spongiosa region) of rats at different time points
(0, 45, or 90 days) after sham or OVX operation (×100).
osteoporosis mainly include hormone replacement, calcium
supplementation, inhibition of bone resorption, and other
methods. However, due to drug side effects, malabsorp-
tion, efficacy instability, poor patient compliance, and other
reasons, the treatment effect is not ideal. More research is
required to further understand the pathophysiology of OPM
and to devise novel effective treatments.
MicroRNAs (miRNAs) are a class of noncoding single-
stranded RNAs encoded by endogenous genes of about 22
nucleotides, typically associating with the 3󸀠UTR region or
coding region of the target genemRNA sequence, which thus
regulates protein expression of the target gene [6, 7]. For
example, it has been reported that miR-142-5p is an impor-
tant noncoding RNA targeting several genes depending on
cellular microenvironments. Recent studies have shown that
a variety of miRNAs play an important regulatory role
in BMMSC cell differentiation [8–10]. However, miRNAs
involved in regulating BMMSC osteogenic differentiation
in osteoporosis are largely unknown. As a major adhesion
protein, vascular cell adhesion molecule 1 (VCAM-1) has
been found to be expressed at lower levels in some diseases
that are characterized by a deficiency or dysfunction in
mesenchymal stem cells, such as aplastic anemia. However,
potential functions of miR-142-5p and VCAM-1 in osteo-
porosis have been hardly reported previously.
Thus, in this study, miRNA sequencing was conducted
in BMMSCs isolated from a rat model of ovariectomy-
(OVX-) induced OPM, from which miRNAs associated with
the development of OPM were screened. After expression
confirmation, miR-142-5p with a clear expression difference
following OVX was selected for subsequent analyses to
study how it regulates the behaviours and functions of
BMMSCs.
2. Results
2.1. Significant Trabecular Bone Loss at Days 45 and 90 in
a Rat Model of Total OVX-Induced Osteoporosis. A bilateral
OVX-induced osteoporosis model was established in the
current study according to a previous study [11], and the
BMD was measured on days 0, 45, and 90 after OVX
Table 1: Results of the bone mineral density in rats of the sham or
OVX groups at different time points after operation.
0 days (mg/cm2) 45 days (mg/cm2) 90 days (mg/cm2)
Sham 174.18 ± 18.66 169.87 ± 15.82 162.29 ± 19.83
OVX 168.78 ± 23.89 145.64 ± 17.80 114.94 ± 19.92
𝑝 value >0.05 <0.05 <0.05
(Table 1). Significant differences in BMD between the sham
and OVX groups at the 45th day and the 90th day (𝑝 <
0.05) suggest significant bone loss in rats at 45 and 90 days
after ovariectomy. As a verification, our histology analyses
of H&E-stained sections of femurs (at the lower secondary
spongiosa region) of rats at different time points after sham
or OVX operation confirmed our BMD findings. It can be
seen that trabecular spacing significantly increased in OVX
rats at day 45 when compared to day 0 or sham control,
and the spacing increased further at the 90th day in OVX
rats when compared to sham rats (Figure 1). These results
reveal thatOVXanimals ondays 45 and 90 showed significant
symptoms of osteoporosis.
2.2. Significantly Increased Expression of miR-142-5p in BMM-
SCs Isolated from OVX-Induced Osteoporotic Rats. BMMSCs
were isolated from days 0, 45, and 90 after sham or OVX
operation and miRNAs were sequenced. Among them, the
miRNAs that had expression differences over 3 folds are
tabulated (Table 2). Furthermore, for expression verification,
BMMSCswere isolated from the sham group andOVX group
of day 45, from which miRNAs were extracted and used in
quantitative PCR analyses of those miRNAs with over 5-fold
differences as revealed from the above sequencing analyses
(Figure 2). As shown, there are significant differences in four
miRNAs between the sham and OVX groups. Among them,
𝑝 values of miR-129-5p and miR-142-5p were both less than
0.01, being 0.0012 and 0.000058, respectively.𝑝 values ofmiR-
146a-5p andmiR-206-3pwere both less than 0.05, being 0.016
and 0.018, respectively. As miR-142-5p was found to have the
lowest 𝑝 value, it was selected to be studied further.
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Table 2: The list of miRNAs that have at least 3-fold changes in the
gene sequencing analyses.
miRNA Fold Change 𝑞 value
rno-miR-129-5p 29.90399529 1.99𝐸 − 228
rno-miR-146a-5p 8.6247 0
rno-miR-363-3p 7.6276 0.00072763
rno-miR-206-3p 7.0579 1.07𝐸 − 32
rno-miR-142-3p 6.9643 8.18𝐸 − 18
rno-miR-142-5p 6.5649 5.45𝐸 − 38
rno-miR-223-5p 6.3947 8.10𝐸 − 05
rno-miR-223-3p 6.1517 1.12𝐸 − 10
rno-miR-139-5p 5.829 6.40𝐸 − 13
rno-miR-6321 4.091 0.00042924
rno-miR-184 3.5614 2.51𝐸 − 05
rno-miR-325-3p 3.4431 0.0084137
rno-miR-455-5p 3.3579 2.04𝐸 − 134
rno-miR-10b-5p 3.3451 0
rno-miR-204-5p 3.2485 1.25𝐸 − 42
rno-miR-708-3p 3.2432 9.74𝐸 − 14
rno-miR-29c-5p 3.1197 6.74𝐸 − 06
rno-miR-140-3p −3.0982 0
rno-miR-541-5p −3.1068 1.72𝐸 − 06
rno-miR-582-5p −3.1309 0.00023355
rno-miR-379-5p −3.438 5.02𝐸 − 13
rno-miR-127-3p −4.1729 2.29𝐸 − 30
rno-miR-129-1-3p −4.7145 1.44𝐸 − 19
rno-miR-129-2-3p −4.7145 1.44𝐸 − 19
2.3. miR-142-5p Inhibited VCAM-1 Expression by Binding
to the 3󸀠UTR Region of VCAM-1. By analysing miRWalk
database to identify mRNA that binds to miR-142-5p, miR-
142-5p was found to be able to bind to the 3󸀠UTR region
of VCAM-1. Consistently, after analysing the transcriptome
sequencing data of BMMSCs from our previous rat OVS
osteoporotic model, the expression of VCAM-1 in BMMSCs
was significantly decreased in the OVX osteoporotic rats
(Figure 3(a)).Thebinding sequence ofmiR-142-5p toVCAM-
1 in the 3󸀠UTR region is shown in Figure 3(b).
To confirm that miR-142-5p indeed binds to VCAM-1
3󸀠UTR region and regulates VCAM-1 expression, the 3󸀠UTR
region of VCAM-1 was extracted and the 8 nucleotides of
the binding domain were knocked down prior to being
constructed into the luciferase expression vector. The effect
of miR-142-5p on luciferase expression was detected by the
dual-luciferase assay (Figure 3(c)). The results revealed that
when VCAM-1 sequence was intact, miR-142-5p significantly
reduced the luciferase activity in the 3󸀠UTR region ofVCAM-
1. However, when the sequence of binding to miR-142-5p
in the 3󸀠UTR region of VCAM-1 was knocked down, the
luciferase activity was not affected by miR-142-5p. Further-
more, cells transfected with miR-142-5p mimic, but not the
negative control mimic, were shown to have a much lower
VCAM-1 protein expression as revealed via Western blotting
analyses (Figure 3(d)). These results showed that miR-142-5p




























































































Figure 2: Relative expression of miRNAs (of >5-fold changes) as
analysed by qPCR in BMMSCs isolated from sham control rats or
OVX-induced osteoporosis rats (𝑛 = 5/group; ∗𝑝 < 0.05 and ∗∗𝑝 <
0.01).
miR-142-5p inhibits the expression of VCAM-1 by binding to
the AUGAAAUA sequence of the 3󸀠UTR region of VCAM-1.
2.4. miR-142-5p Inhibited Migration of BMMSCs. Themigra-
tion ability of BMMSCs is related to the level of osteogen-
esis, and impaired osteogenesis is an important part of the
development of osteoporosis. Therefore, to study whether
miR-142-5p affects the migration of BMMSCs, the BMMSCs
were isolated from sham and OVX groups and their abilities
to migrate in a Transwell migration assay were examined
following transfectionwith themiR-142-5pmimic or negative
control mimic (Figure 4). The migration ability of BMM-
SCs transfected with miR-142-5p mimic was significantly
decreased, while there were no significant differences in
the group transfected with negative control mimic. The
results showed that miR-142-5p could inhibit the migration
of BMMSCs by inhibiting the expression of VCAM-1.
3. Discussion
Estrogen deficiency is one of the major risk factors of osteo-
porosis. Osteoporosis results from imbalanced and negative
bone remodelling when osteogenesis (carried out by bone
forming cells osteoblasts) is less than bone resorption (carried
out by resorptive cells osteoclasts). BMMSCs are precursors
of osteoblasts, and when BMMSCs fail to migrate and differ-
entiate to osteoblasts in areas needed, decreased osteogenesis
would ensure causing osteoporosis [12]. However, how the
migration of BMMSCs is regulated in osteoporosis remains
unclear.
It has been reported that miRNAs regulate gene expres-
sion in physiological and pathophysiologic process [13].












































Figure 3: miR-142-5p can inhibit the expression of VCAM-1. (a) Results of VCAM-1 in BMMSCs transcriptome sequencing. (b) A schematic
diagramofmiR-142-5p paringwith the 3󸀠UTRarea ofVCAM-1, as well as the schematic diagramof the luciferase expression vector constructs,
respectively, with wild-type (WT) and mutant (Mut) VCAM-1 sequences. (c) Test results of the dual-luciferase activity assay; 𝑛 = 3 for each
group. (d) Transfection with the miR-142-5p mimic, but not the negative control (NC) mimic, inhibits protein expression of VCAM-1 as
revealed by Western blotting analyses. ∗𝑝 < 0.05.
NC mimic miR-142-5p mimic
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Figure 4: miR-142-5pmimic, but not the negative control (NC)mimic, inhibited themigration ability of bonemarrow-derivedmesenchymal
stem cells. (a) Representative images of migrated cells in a Transwell cell migration assay. (b) Statistical analyses of three Transwell migration
experiments. ∗𝑝 < 0.05.
Although dozens of miRNAs have been suggested to play
roles in osteoporosis [14], their regulatory roles in osteo-
porosis are unclear. In this present study, using an OVX
osteoporosis model in rats, many miRNAs were found to
have significant changes in expression, and, particularly,miR-
142-5p was found to have the most significant induction in
BMMSCs of rats with OVX-induced osteoporosis.
Previously, miR-142-5p has been reported to be able to
regulate several genes depending on cellular microenviron-
ments, and its aberrant expression has been detected in
various disorders. Song and Kim reported that miR-142-5p
levels correlated to A𝛽42 expression [15]. Sharma reviewed
that miR-142-5p can regulate inflammation and immune
responses [16]. miR-142-5p was also reported to play roles in
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colon cancer and squamous cell carcinoma [17, 18]. However,
the target gene(s) and molecular mechanism of miR-142-5p
action in osteoporosis are not clear yet.
The current study has investigated the relationship
between miR-142-5p and VCAM-1 in the osteoporosis set-
ting. VCAM-l is the 100 kDa or 110 kDa transmembrane gly-
coprotein named CD106, a high-affinity adhesion molecule,
which is commonly expressed in endothelial cells, bone
marrow stromal cells, smooth muscle cells, macrophages,
and dendritic cells [19]. VCAM-1 is an adhesion protein
important in cell-cell recognition and it playsmultiple roles in
inflammation, cell differentiation and development of organs,
immune responses, lymphocyte homing and recycling, and
malignant metastasis [20]. VCAM-1 in the immune cells is
known to contribute to their activation and migration [21].
Furthermore, VCAM-1 is expressed at lower levels in some
diseases characterizedwithmesenchymal stem cell deficiency
or dysfunction, such as aplastic anemia. In the current study,
based on our previous transcriptome sequencing analysis,
miR-142-5p was proven to bind 3󸀠UTR in VCAM-1 gene
and inhibit BMMSC migration by downregulating VCAM-
1 expression. Due to the important role of VCAM-1 in
migration of BMMSCs and the critical role of BMMSCs
migration to site of bone formation prior to their osteogenic
commitment for new bone formation during physiological
bone remodelling and bone fracture healing, the findings in
the current study indicated the important role of miR-142-
5p in osteoporosis development involving targeting VCAM-1
and inhibiting BMMSC migration.
4. Materials and Methods
4.1. Animals and OVX-Induced Osteoporosis Model. All pro-
cedures were approved by the Animal Care and Use Com-
mittee of Kunming Medical University. 30 ten-week-old
healthy specific-pathogen-free (SPF) female Sprague-Dawley
(SD) rats were purchased from Vital River (Beijing, China).
All rats were preserved under standard housing laboratory
conditions. After one week of adaptation to the diet and
the new environment, the rats were randomly divided into
2 groups: ovariectomized group (OVX, 𝑛 = 15) and sham-
operated group (sham, 𝑛 = 15). At 12 weeks of age, OVX
group underwent OVX (removal of bilateral ovaries) after
being anesthetized via i.p. injection of pentobarbital sodium
in PBS at 30mg/kg as we described and according to the
classic protocol [11, 22, 23]. For the sham operation group, the
same volume of fat pad was taken out instead of the bilateral
ovaries.
4.2. Specimen Collection, BMD Measurement, and Histology
Staining. The rats were sacrificed with carbon dioxide over-
dose at 45 days and 90 days after operation. The BMDs of
left femurs were measured using dual-energy X-ray absorp-
tiometry (DEXA) (Prodigy, Lunar, GE Healthcare, Madison,
WI) (mg/cm2). Femoral specimens were fixed with 4%
paraformaldehyde, decalcified (10% EDTA-2Na, 0.1M Tris
buffer, pH 7.3), and embedded in paraffin sections. Sections
of 4 𝜇m were cut, stained by H&E, and photographed under
light microscope.
4.3. Isolation and Cultivation of BMMSCs. For isolation of
BMMSCs, rats were sacrificed by cervical dislocation and
soaked in 75% ethanol for 10min, and then femurs and tibias
were dissected under sterile condition and washed with PBS
three times. After removing epiphyses, bones were flushed
with ECMmedium (ScienCell, Carlsbad, CA) supplemented
with 10% fetal bovine serum (Gibco, Grand Island, NY)
and 100U/ml penicillin and streptomycin (Sigma-Aldrich, St.
Louis, MO). The isolated bone marrow samples were made
into single cell suspension and centrifuged at 1000 rpm/min
for 5min, and after the supernatant was discarded, the cells
were resuspended in a concentration of 1 × 109 L−1 in a
25 cm2 plastic culture flask for incubation at 37∘C in a 5%
CO
2
incubator. During the primary stromal cell culture,
the medium was replaced after 48 h, and the fresh medium
was replaced every 3 days. For passage culture, cells were
trypsinised and then subcultured at 1 : 2 ratio.
4.4. MiRNA Sequencing. For miRNA sequencing purpose,
after BMMSCs were cultured for 10 days, 1mL TRIzol
(Invitrogen, Carlsbad, CA) was added to 1 × 107 cells of
BBMSCs. Then, the samples were sent to Novogene (Beijing,
China) for sequencing and data analysis.
4.5. Quantitative PCR (qPCR). The intracellular miRNA was
extracted by miRNA extraction kit (DP501, Tiangen, Beijing,
China), and reverse transcription was performed using RT-
PCR kit (KR108, Tiangen). For quantitative PCR, ABI7500
real-time PCR system (Applied Biosystems, Beijing, China)
was used to perform quantitative experiments using SYBR
Green kit (FP201, Tiangen).The expression levels ofmiR-142-
5p and other miRNAs were normalized by U6. The primer
sequences are listed in Table 3.
4.6. Western Blotting Analyses. Cells were lysed in RIPA
buffer plus protease inhibitors (Roche, South San Francisco,
CA). Equal amounts of proteins were loaded and separated
on 10% SDS-PAGE and then transferred to a nitrocellulose
membrane (BD Biosciences, San Jose, CA), blocked by
incubation with 5% fat-free milk in TBST buffer (150mM
NaCl, 50mMTris-HCl, 0.5% Tween 20, pH 7.6) at room tem-
perature for 1 h.Themembraneswere incubatedwith primary
antibodies against vascular cell adhesionmolecule 1 (VCAM-
1) (ab134047, Abcam, Cambridge, UK) or against the internal
control 𝛽-actin (Sigma-Aldrich) at 4∘C overnight and then
with horseradish peroxide-conjugated secondary antibodies
at room temperature for 1 h, prior to being developed with
ECL reagent (Thermo Scientific, Waltham, MA) as described
[24].
4.7. Dual-Luciferase Assay. The 3󸀠UTR region of VCAM-1
was amplified by PCR and constructed into pGL3 vector.
The upstream primer was 5󸀠-CTAGCTAGCCGTCTGAAC-
TGTTGGAG-3󸀠 with XhoI as the cleavage site, and the
downstream primer was 5󸀠-CCCAAGCTTCTTAATCAG-
TATACCATC-3󸀠 with HindIII as the cleavage site. The
mutant primers were as follows: upstream: 5󸀠-TTGAAACTT-
CAGCCTAA-3󸀠, downstream: 5󸀠-AAACAAAAAGGTGAC-
AC-3󸀠. Using transfection reagent Lipofectamine
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Table 3: The sequences of reverse transcriptional primers and qPCR primers used in miRNA quantitative PCR.
Primers Sequences (5󸀠-3󸀠)
rno-miR-129-5p reverse transcription sequence GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGCAAGC
rno-miR-129-5p qPCR upstream primer GCGGCTTTTTGCGGTCTGG
rno-miR-146a-5p reverse transcription sequence GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAACCCA
rno-miR-146a-5p qPCR upstream primer GCGGTGAGAACTGAATTCCA
rno-miR-363-3p reverse transcription sequence GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACAGAT
rno-miR-363-3p qPCR upstream primer GCGGAATTGCACGGTATCC
rno-miR-206-3p reverse transcription sequence GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCACAC
rno-miR-206-3p qPCR upstream primer GCGGTGGAATGTAAGGAAGT
rno-miR-142-3p reverse transcription sequence GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCCATA
rno-miR-142-3p qPCR upstream primer GCGGTGTAGTGTTCCTACTT
rno-miR-142-5p reverse transcription sequence GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGTAGT
rno-miR-142-5p qPCR upstream primer GCGGCATAAAGTAGAAAGC
rno-miR-223-5p reverse transcription sequence GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAACTC
rno-miR-223-5p qPCR upstream primer GCGGCGTGTATTTGACAAGCT
rno-miR-223-3p reverse transcription sequence GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGGGGTA
rno-miR-223-3p qPCR upstream primer GCGGTGTCAGTTTGTCAAA
rno-miR-139-5p reverse transcription sequence GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTGGAG
rno-miR-139-5p qPCR upstream prime GCGGTCTACAGTGCACGTGT
qPCR common downstream sequence GTGCAGGGTCCGAGGT
2000 (Invitrogen, Carlsbad, CA), HEK293T cells were
cotransfected with pGL3-VCAM-1-3󸀠UTR-WT (with wild-
type VCAM-1 sequence) or pGL3-VCAM-1-3󸀠UTR-MUT
(with 8 nucleotides of the VCAM-1 3󸀠UTR region being
mutated) (see below) and pRL and miR-142-5p mimic or
negative control (NC) mimic (Genscript, Beijing, China).
The cells were harvested after 48 hours to detect dual-
luciferase activities using dual-luciferase assay kit (Promega,
Madison, WI) as described [25].
4.8. Statistical Analyses. GraphPad Prism 7.0 was used to
evaluate data. The experimental data was expressed as 𝜒 ± 𝑠,
and the data was analysed by 𝑡-test or single-factor analysis of
variance. All experiments were repeated at least three times
to show representative results. 𝑝 < 0.05 was considered
statistically significant.
5. Conclusions
miR-142-5p has been proven in the current study to be the
most significantly induced miRNA in BMMSCs and bind to
3󸀠UTR of VCAM-1 to inhibit VCAM-1 expression in OVX-
induced osteoporosis in rats. This study has also shown that
downregulated VCAM-1 inhibits migration of BMMSCs in
osteoporosis. Thus, this work has presented evidence for a
potentially new target for diagnosis, prevention, and therapy
of osteoporosis.
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